HTL Biotechnology inaugurated its new production unit, HTL8, at its Javené site in Ille-et-Vilaine, France. The unit, dedicated to the manufacture of pharmaceutical-grade polynucleotides, represents a USD 16.54 million investment.
A Structuring Investment in Javené
According to the company, the investment marks a structuring step in the group's international development strategy and in the diversification of its biopolymer portfolio.
HTL states that the new capacity responds to growing global demand for biopolymers intended for the most demanding therapeutic applications.
Part of a Broader Investment Plan
HTL8 sits within HTL Biotechnology's 2022-2026 investment plan of USD 110.28 million, which the company says has strongly contributed to its international development and the diversification of its portfolio in recent years.
The company describes itself as a visionary and pioneering player in the mastery of polynucleotides for 45 years and positions the new unit as a way of consolidating its premium positioning in the innovative segment of regenerative medicine while supporting the growth of global demand, particularly in Asian markets.
François Fournier, CEO of HTL Biotechnology, emphasized the unit's place within the broader plan.
"This new unit is fully in line with the USD 110.28 million investment plan launched in 2022. We are very committed to monitoring our markets and anticipating their developments by placing customer expectations at the heart of our strategy. Equipping ourselves with the most modern industrial capabilities to live up to our ambitions is key in this context. HTL8 is a perfect illustration of this: it anchors in France an industrial excellence capable of shining on a global scale, supporting our customers closely in their markets and contributing, through increasingly innovative pharmaceutical-grade biopolymers, to the healthcare solutions of tomorrow," Fournier declared.
Trusted by Leading EPCs & Manufacturers
Find the Latest Pharmaceutical Plant Projects in France
Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information
Request Free Trial → Learn More →
No credit card Up-to-date coverage
What Polynucleotides Are and Where They Come From
Polynucleotides are biopolymers made up of chains of nucleotides that are attracting increasing interest for their regenerative properties. According to HTL Biotechnology, these properties include the ability to promote tissue repair, hydration, and improved skin quality.
The company manufactures its polynucleotides from DNA extracted from wild Alaskan salmon milt, a co-product of the salmon industry that is recovered and used as a pharmaceutical raw material. HTL Biotechnology draws on 45 years of expertise in the production of high-quality biopolymers.
Purification Capabilities and Target Applications
The new unit is dedicated to the purification of pharmaceutical-grade polynucleotides. HTL says it strengthens the company's industrial capabilities and supports the development of new applications, particularly in regenerative medicine, ophthalmology, and dermatology, including wound healing.
HTL8 has been designed to meet demanding industrial and pharmaceutical manufacturing standards. The company states that the unit combines advanced equipment and automation with enhanced control of critical process parameters and rigorous quality and safety requirements.
HTL frames the facility as reinforcing its positioning as a key player in health innovation and as reflecting its approach to industrial excellence: combining advanced equipment and robust processes with the specialist expertise of the teams operating them.
About HTL Biotechnology
HTL Biotechnology is a French biotech company and describes itself as a world leader in the development and bioproduction of pharmaceutical-grade biopolymers, including Hyaluronic Acid and Polynucleotides. These biopolymers are used by healthcare companies to develop treatments in cutting-edge therapeutic fields such as ophthalmology, dermatology, medical aesthetics, and rheumatology.
The company recently strengthened its position by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII, based in New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3), obtained from a world-class scientific research center.
To meet the world's growing need for biopolymers, HTL also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI, in Massachusetts).
Historically based in Javené in Brittany, the company combines production, innovation, R&D, and quality activities on its French site and employs nearly 300 people worldwide.
Context and Outlook
The inauguration of HTL8 arrives as the 2022-2026 investment plan approaches its final year.
The company presents the unit as anchoring pharmaceutical-grade polynucleotide production in France while serving international markets, with a particular emphasis on Asian demand. Press contact for the announcement is Matthieu Laude of APCO.
Stay Ahead of France's Shifting Chemical Manufacturing Landscape
France's chemical sector is undergoing a profound transformation, driven by decarbonization mandates, feedstock volatility, and a wave of brownfield and greenfield investments across the continent. The real question is not whether new projects are emerging, but whether you will see them before your competitors do.
Tracking capital-intensive chemical developments, from specialty polymers to bio-based feedstocks, manually across dozens of French markets is inefficient and risky. Opportunities surface, contracts are awarded, and construction begins long before news reaches your desk.
The Global Project Tracking (GPT) platform by Blackridge Research eliminates that gap. It delivers verified, real-time intelligence on chemical industry projects across France, so your business development, sales, and strategy teams can act on actionable data, not lagging reports.
Upcoming Projects
Tender Notices
Contract Awards
Projects Under Construction
Completed Projects
Ready to position your company at the center of France's next wave of chemical investment? Book a Free Demo and experience the Global Project Tracking (GPT) platform by Blackridge Research firsthand.
Leave a Comment
We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.
We read every comment and do our best to respond to them all.